Luminex Corporation
8
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
A Multi-Site Clinical Evaluation of the ARIES Clostridium Difficile Assay in Symptomatic Patients
Role: lead
A Multi-Site Clinical Evaluation of the ARIES Group A Strep Assay in Symptomatic Patients
Role: lead
Clinical Evaluation of the ARIES Group B Streptococcus (GBS) Assay
Role: lead
A Multi-Site Clinical Evaluation of the ARIES Flu Assay in Symptomatic Patients
Role: lead
A Multi-Site Clinical Evaluation of the ARIES Norovirus Assay
Role: lead
A Two Arm, Multi-Site Clinical Evaluation of the ARIES HSV 1&2 Assay in Symptomatic Patients
Role: lead
Use of Vein Viewer for Insertion of Peripheral Venous Cannula in Pediatric Patients With Difficult Intravenous Access
Role: collaborator
Clinical Evaluation of NeoPlex4 Assay and NeoPlex System
Role: lead
All 8 trials loaded